COVID-19 Clinical Research Studies

The paper develops a 6-mRNA classifier using non-COVID-19 viral infection data to predict COVID-19 severity, achieving high accuracy in independent cohorts.

The paper examines sex differences in COVID-19 outcomes and immune responses using single-cell RNA-sequencing and clinical data, finding higher risk for males and potential mechanisms for sex-specific treatments.

The paper identifies a blood gene signature predictive of poor outcomes in SARS-CoV-2 infection by analyzing its cellular sources in single-cell data.

This study uses Mendelian randomization to show that genetically proxied IL-6 signaling inhibition reduces COVID-19 risk but increases pneumonia risk.

The paper reports Whole Exome Sequencing analysis of 35 hospitalized COVID-19 patients, identifying pathogenic mutations linked to virus infection susceptibility and disease progression.

This study uses single-cell RNA sequencing to analyze immune responses in COVID-19 patients, identifying key immune cell changes and molecular pathways linked to disease severity.

The paper examines how genetic variants of coagulation-related proteins interacting with SARS-CoV-2 may influence COVID-19 severity, particularly in minority populations.

The paper uses single-cell analysis to show that Tocilizumab reduces monocyte-driven inflammation in severe COVID-19 but does not fully suppress immune responses.

This study investigates heparin's ability to inhibit IFN-gamma and IL-6 signaling pathways in COVID-19 to prevent cytokine release syndrome.

The paper investigates the potential link between heme levels and COVID-19 pathogenesis by analyzing protein interactions and common pathways.

The paper investigates the association between ApoE e4 genotype and severe COVID-19 in the UK Biobank community cohort, finding a link with increased risk of severe outcomes.

The paper examines sex differences in ACE2 and TMPRSS2 expression in prostate and lung epithelial cells, finding higher ACE2 expression in male lung type II pneumocytes and co-expression in prostate club cells.

The paper identifies clonal chromosomal mosaicism and loss of chromosome Y as risk factors for severe SARS-CoV-2 outcomes in elderly males.

In healthy human liver scRNA-seq, ACE2 is detected in 59.7% of cholangiocytes but 2.6% of hepatocytes, so 2019-nCoV may target bile duct cells rather than hepatocytes.